Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07361224
What this trial is testing

Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.

Who this might be right for
Large B-Cell Lymphoma (LBCL)
Tel-Aviv Sourasky Medical Center 12
Very early researchUnknownNCT04191941
What this trial is testing

Treatment of Hematological Malignancy With Novel CAR-T Cells.

Who this might be right for
B-cell Non Hodgkin LymphomaB-cell Acute Lymphoblastic LeukemiaMultiple Myeloma
Timmune Biotech Inc. 9
Not applicableNot Yet RecruitingNCT07412405
What this trial is testing

This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R

Who this might be right for
Adult B-cell Acute Lymphoblastic LeukemiaFollicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)+2 more
GUSTAVO SALGUERO 12
Early research (Phase 1)UnknownNCT03881761
What this trial is testing

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Who this might be right for
B-Cell Lymphoma Stage IRefractoryRelapsed
Henan Cancer Hospital 50
Very early researchLooking for participantsNCT06785519
What this trial is testing

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

Who this might be right for
Lupus Nephritis
He Huang 9
Testing effectiveness (Phase 2)Looking for participantsNCT06688799
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Beijing GoBroad Hospital 18
Testing effectiveness (Phase 2)UnknownNCT03754764
What this trial is testing

A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy

Who this might be right for
Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T ACI
Chinese PLA General Hospital 80
Early research (Phase 1)Active Not RecruitingNCT06294236
What this trial is testing

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Who this might be right for
Lupus ErythematosusSystemic Lupus ErythematosusSLE (Systemic Lupus)+3 more
Sana Biotechnology 7
Testing effectiveness (Phase 2)WithdrawnNCT05613348
What this trial is testing

CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoma, Unspecified
Zhujiang Hospital
Early research (Phase 1)Ended earlyNCT02465983
What this trial is testing

Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
University of Pennsylvania 4
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05459870
What this trial is testing

CAR-T Cells Targeting Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
Shenzhen Geno-Immune Medical Institute 30
Testing effectiveness (Phase 2)UnknownNCT02819583
What this trial is testing

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)Looking for participantsNCT06364423
What this trial is testing

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-CellB-Lymphocytic Leukemia, ChronicB-Cell Chronic Lymphocytic Leukemia+4 more
National Cancer Institute (NCI) 132
Testing effectiveness (Phase 2)UnknownNCT05381662
What this trial is testing

CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment

Who this might be right for
Acute Lymphoblastic Leukemia in Remission
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 10
Testing effectiveness (Phase 2)UnknownNCT03191773
What this trial is testing

Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaLymphoma
Second Affiliated Hospital of Guangzhou Medical University 100
Early research (Phase 1)UnknownNCT03344705
What this trial is testing

Safety and Efficacy Evaluation of IM19 Cells

Who this might be right for
Hematological Malignancies
Beijing Immunochina Medical Science & Technology Co., Ltd. 20
Early research (Phase 1)UnknownNCT05528887
What this trial is testing

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological MalignanciesLymphomaMyeloma+1 more
The Affiliated People's Hospital of Ningbo University 10
Testing effectiveness (Phase 2)WithdrawnNCT06009107
What this trial is testing

HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Early research (Phase 1)Ended earlyNCT04160195
What this trial is testing

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Who this might be right for
Lymphoma, B-CellLymphoma, Non-hodgkinsChronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Looking for participantsNCT06847269
What this trial is testing

CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

Who this might be right for
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital 25
Next Page